search
Back to results

Reducing Concurrent Opioid-Benzodiazepine Prescriptions

Primary Purpose

Adverse Drug Effect of Opioids, Adverse Drug Effect of Benzodiazepines

Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
E-mail Alert
Sponsored by
Walter Reed National Military Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Adverse Drug Effect of Opioids focused on measuring Care coordination, Opioid, Benzodiazepine, Behavioral science, Behavioral economics, Nudge, Fragmentation of care, Concurrent prescribing

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Patient had an overlapping opioid-benzodiazepine prescription
  • At least one of the patient's providers (opioid prescribers, benzodiazepine prescribers, and/or PCM) is in the NCR

Exclusion Criteria:

  • Patient has a cancer diagnosis
  • Patient is receiving palliative care
  • Patient is under 18
  • Patient was previously allocated to a study condition

Sites / Locations

  • Walter Reed National Military Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

No Intervention

Arm Label

E-Mail Alert

As-Usual

Arm Description

Send email to the patient's opioid prescriber(s), benzodiazepine prescriber(s), and/or primary care manager.

As-usual (no email) approach.

Outcomes

Primary Outcome Measures

Overlapping Days
Overlapping days of opioids and benzodiazepines, determined using the dates of service and days supply of the prescription drug fills
Opioid Days
Days of opioids received
Benzodiazepine Days
Days of benzodiazepines received

Secondary Outcome Measures

Full Information

First Posted
March 19, 2019
Last Updated
May 18, 2021
Sponsor
Walter Reed National Military Medical Center
Collaborators
United States Department of Defense, General Services Administration (GSA)
search

1. Study Identification

Unique Protocol Identification Number
NCT03887247
Brief Title
Reducing Concurrent Opioid-Benzodiazepine Prescriptions
Official Title
Reducing Concurrent Opioid-Benzodiazepine Prescriptions Through Provider Intervention
Study Type
Interventional

2. Study Status

Record Verification Date
April 2021
Overall Recruitment Status
Unknown status
Study Start Date
June 6, 2019 (Actual)
Primary Completion Date
July 29, 2021 (Anticipated)
Study Completion Date
June 1, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Walter Reed National Military Medical Center
Collaborators
United States Department of Defense, General Services Administration (GSA)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this effort is to use informative e-mails to improve the process of prescribing of opioids and benzodiazepines within the National Capital Region/Military Health System (NCR/MHS), with the aim of decreasing concurrent opioid and benzodiazepine prescribing.
Detailed Description
The purpose of this effort is to use low-cost informative e-mails to improve the process of prescribing of opioids and benzodiazepines within the National Capital Region/Military Health System (NCR/MHS), with the aim of decreasing concurrent opioid and benzodiazepine prescribing. Both the VA/DoD Clinical Practice Guideline for Opioid Therapy for Chronic Pain (2017) and the CDC Guideline for Prescribing Opioids for Chronic Pain (2016) strongly recommend against the concurrent use of opioids and benzodiazepines. Taken together, these drugs could cause respiratory depression, enhanced sedation, and death. The intervention population will be prescribers and primary care managers associated with patients who have recently received concurrent prescriptions of opioids and benzodiazepines. Using a randomized approach, we will allocate the NCR/MHS providers associated with patients with concurrent prescriptions for opioids and benzodiazepines to one of two conditions: E-mail alert - A messaging approach, in which we will send encrypted emails to the patient's opioid and benzodiazepine prescriber(s) and primary care manager that identify the concurrent prescriptions and detail the patient's prescription history, inform them of the VA/DoD guideline and risk to patient, and provide action steps and relevant resources. When multiple providers are involved, the email message will also encourage coordination across providers and provide relevant contact information As-Usual - An as-usual approach, in which providers are not sent messages. These providers can access patient information through the MHS Opioid Registry as before.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Adverse Drug Effect of Opioids, Adverse Drug Effect of Benzodiazepines
Keywords
Care coordination, Opioid, Benzodiazepine, Behavioral science, Behavioral economics, Nudge, Fragmentation of care, Concurrent prescribing

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
2234 (Actual)

8. Arms, Groups, and Interventions

Arm Title
E-Mail Alert
Arm Type
Active Comparator
Arm Description
Send email to the patient's opioid prescriber(s), benzodiazepine prescriber(s), and/or primary care manager.
Arm Title
As-Usual
Arm Type
No Intervention
Arm Description
As-usual (no email) approach.
Intervention Type
Behavioral
Intervention Name(s)
E-mail Alert
Intervention Description
Encrypted email to the following providers: the patient's opioid prescriber(s), benzodiazepine prescriber(s), and/or primary care manager. If there is more than one provider, they are copied together on the same message. The email identifies the concurrent prescriptions, details the patient's prescription history, includes relevant VA/DoD guidelines, states the risk of concurrent prescribing to patient, and provides action steps and relevant resources. When multiple providers are involved, the message encourages the providers to coordinate with each other and provides provider contact information to facilitate this communication.
Primary Outcome Measure Information:
Title
Overlapping Days
Description
Overlapping days of opioids and benzodiazepines, determined using the dates of service and days supply of the prescription drug fills
Time Frame
90 days
Title
Opioid Days
Description
Days of opioids received
Time Frame
90 days
Title
Benzodiazepine Days
Description
Days of benzodiazepines received
Time Frame
90 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Patient had an overlapping opioid-benzodiazepine prescription At least one of the patient's providers (opioid prescribers, benzodiazepine prescribers, and/or PCM) is in the NCR Exclusion Criteria: Patient has a cancer diagnosis Patient is receiving palliative care Patient is under 18 Patient was previously allocated to a study condition
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert E Brutcher, PharmD,PhD
Organizational Affiliation
Walter Reed National Military Medical Center and Uniformed Services University of the Health Sciences
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Alan Sim, PhD
Organizational Affiliation
Defense Health Agency
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Elana Safran, MPP
Organizational Affiliation
General Services Administration (GSA)
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Adam Sacarny, PhD
Organizational Affiliation
General Services Administration and Columbia University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Mary Steffel, PhD
Organizational Affiliation
General Services Administration and Northeastern University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Christopher J Spevak, MD, MPH, JD
Organizational Affiliation
Walter Reed National Medical Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Walter Reed National Military Medical Center
City
Bethesda
State/Province
Maryland
ZIP/Postal Code
20889
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
36218952
Citation
Sacarny A, Safran E, Steffel M, Dunham JR, Abili OD, Mohajeri L, Oh PT, Sim A, Brutcher RE, Spevak C. Effect of Pharmacist Email Alerts on Concurrent Prescribing of Opioids and Benzodiazepines by Prescribers and Primary Care Managers: A Randomized Clinical Trial. JAMA Health Forum. 2022 Sep 2;3(9):e223378. doi: 10.1001/jamahealthforum.2022.3378.
Results Reference
derived

Learn more about this trial

Reducing Concurrent Opioid-Benzodiazepine Prescriptions

We'll reach out to this number within 24 hrs